Karam Chafic
Department of Neurology, University of Pennsylvania, Philadelphia.
Neurol Clin Pract. 2022 Jun;12(3):258-262. doi: 10.1212/CPJ.0000000000001150.
The purpose of this review is to give an update on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
There are several recent developments in CIDP, the major one being the 2021 second revision of the European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Other updates address therapy in CIDP, antibodies, serum neurofilament light chain, chronic immune sensory polyradiculopathy (CISP) and CIDP mimics.
CIDP criteria continue to be refined and some disorders are now excluded from the classification. Treatment options are expending and promising biomarkers are being studied.
本综述旨在提供慢性炎性脱髓鞘性多发性神经根神经病（CIDP）的最新进展。
CIDP近期有多项进展，主要的一项是2021年欧洲神经病学学会/周围神经学会关于慢性炎性脱髓鞘性多发性神经根神经病诊断和治疗指南的第二次修订。其他更新内容涉及CIDP的治疗、抗体、血清神经丝轻链、慢性免疫感觉性多发性神经根病（CISP）以及CIDP的模仿疾病。
CIDP的诊断标准在不断完善，一些疾病现在已被排除在分类之外。治疗选择在不断扩展，并且正在研究有前景的生物标志物。
